Nikkei Asia BusinessCodex · 实盘不做把握 7/10
北京时间·源无时间·以抓取为准·⟳ 抓取 12:45:20·⚡ 决策 08-05 16:42:35 +3h57m·83.1 天前
武田希望将登革热疫苗Qdenga纳入印度国家免疫计划
印度监管批准Qdenga发生在上月，本条新增信息只是公司高管表示希望纳入国家免疫计划。
📄 原文Nikkei Asia Business↗ 原文
Takeda aims for dengue vaccine inclusion in India's shots program
MUMBAI -- Japanese drugmaker Takeda Pharmaceutical is aiming to have its dengue vaccine become a part of India's nation…
不做 武田药品（4502.JP）
本条只是争取进入印度免疫计划，尚无正式纳入、采购量或价格；相对武田体量缺少可量化短期增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-05 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 报道武田希望Qdenga进入印度国家免疫计划，并称印度监管批准发生在上月；本条不是正式采购或纳入公告。市场反应:4502.JP当日收盘5269日元，较前收5286日元下跌0.32%。
关键理由
- 印度监管批准Qdenga发生在上月，本条新增信息只是公司高管表示希望纳入国家免疫计划。
- 印度去年感染约12万人提供潜在市场，但尚未确认政府采购、价格、渗透率或纳入时间，无法估算对武田收入的短期增量。
- 武田为大型药企，单一疫苗在印度的未落地计划不足以推动短期市值级重定价。
主要风险
- 若后续正式纳入国家免疫计划并披露采购量或价格，才需要重新评估商业化量级。
工具调用 · 历史记录,结果未知(2 种)
- normalize_ticker · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 714 字
MUMBAI -- Japanese drugmaker Takeda Pharmaceutical is aiming to have its dengue vaccine become a part of India's national immunization program, a senior company executive said, after the country's regulators approved the product last month.
Jab recently approved for disease that infected 120,000 people last year
Takeda Pharmaceutical's Qdenga is the first vaccine to ever be approved for dengue prevention by India's Central Drugs Standard Control Organisation. © Reuters
MUMBAI -- Japanese drugmaker Takeda Pharmaceutical is aiming to have its dengue vaccine become a part of India's national immunization program, a senior company executive said, after the country's regulators approved the product last month.
Jab recently approved for disease that infected 120,000 people last year
Takeda Pharmaceutical's Qdenga is the first vaccine to ever be approved for dengue prevention by India's Central Drugs Standard Control Organisation. © Reuters
MUMBAI -- Japanese drugmaker Takeda Pharmaceutical is aiming to have its dengue vaccine become a part of India's national immunization program, a senior company executive said, after the country's regulators approved the product last month.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。